Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Hasegawa, Akinori ^a   Sato, Kengo ^a   Shirai, Remina ^a   Watanabe, Rena ^a   Yamamoto, Keigo ^a   Watanabe, Kaho ^a   Nohtomi, Kyoko ^b   Hirano, Tsutomu ^b   Watanabe, Takuya ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 1; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; UROCORTIN I; APOLIPOPROTEIN E; CHOLESTEROL; UCN1 PROTEIN, HUMAN; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FOAM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ATHEROSCLEROSIS; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; HYPOTENSION; INFLAMMATION; METABOLISM; MONOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASODILATATION;

ANIMALS; ANTIGENS, CD36; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; EXTRACELLULAR MATRIX; HUMANS; HYPOTENSION; INFLAMMATION; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; UROCORTINS; VASODILATION;

EID: 84914696664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110866     Document Type: Article

References (45)

1. Ross R, Agius L (1992) The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia 35 Suppl 2: S34-S40.
2. Allahverdian S, Pannu PS, Francis GA (2012) Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res 95: 165-172.
3. Sdi/Cip/Waf1 in monocyte adhesion to endothelial cells. Atherosclerosis 212: 116-122.
4. Richards M, Rademaker M (2013) Urocortins. In: Kastin AJ, editor. Handbook of biologically active peptides, edn 2. San Diego: Elsevier. pp. 1428-1436.
5. Davidson SM, Yellon DM (2009) Urocortin: a protective peptide that targets both the myocardium and vasculature. Pharmacol Rep 61: 172-182.
6. Takahashi K (2012) Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system. Int J Endocrinol 2012: 395284.
7. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J et al. (2005) Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 579: 4259-4264.
8. Boonprasert P, Lailerd N, Chattipakorn N (2008) Urocortins in heart failure and ischemic heart disease. Int J Cardiol 127: 307-312.
9. Knight RA, Chen-Scarabelli C, Yuan Z, McCauley RB, Di Rezze J et al. (2008) Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury. FEBS Lett 582: 984-990.
10. Ikeda K, Tojo K, Inada Y, Takada Y, Sakamoto M et al. (2009) Regulation of urocortin I and its related peptide urocortin II by inflammatory and oxidative stresses in HL-1 cardiomyocytes. J Mol Endocrinol 42: 479-489.
11. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K et al. (2006) Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 43: 131-138.
12. Emeto TI, Moxon JV, Rush C, Woodward L, Golledge J (2011) Relevance of urocortins to cardiovascular disease. J Mol Cell Cardiol 51: 299-307.
13. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG et al. (2009) Plasma urocortin 1 in human heart failure. Circ Heart Fail 2: 465-471.
14. Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S et al. (2010) Plasma urocortin in acute myocardial infarction patients. Eur J Clin Invest 40: 874-882.
15. Zaiou M, Benachour H, Marteau JB, Visvikis-Siest S, Siest G (2009) Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Curr Pharm Des 15: 3193-3206.
16. Konii H, Sato K, Kikuchi S, Okiyama H, Watanabe R et al. (2013) Stimulatory effects of cardiotrophin 1 on atherosclerosis. Hypertension 62: 942-950.
17. 1 on macrophage foam cell formation and atherosclerosis. Circ Res 105: 500-510.
18. Watanabe T, Nishio K, Kanome T, Matsuyama T, Koba S et al. (2008) Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 117: 638-648.
19. Watanabe T, Suguro T, Kanome T, Sakamoto Y, Kodate S et al. (2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46: 738-744.
20. López-Andrés N, Fortuno MA, Diez J, Zannad F, Lacolley P et al. (2010) Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens 28: 1261-1272.
21. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K et al. (2011) Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54: 2649-2659.
22. Onorati F, Chen-Scarabelli C, Knight R, Stephanou A, Mohanti B et al. (2013) Targeting urocortin signaling pathways to enhance cardioprotection: is it time to move from bench to bedside? Cardiovasc Drugs Ther 27: 451-463.
23. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT et al. (2004) Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89: 1402-1409.
24. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MTet al. (2005) Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 109: 381-388.
25. Chen ZW, Huang Y, Yang Q, Li X, Wei W et al. (2005) Urocortin-induced relaxation in the human internal mammary artery. Cardiovas Res 65: 913-920.
26. Yang C, Liu X, Li S (2010) Effect of long-term treatment with urocortin on the activity of somatic angiotensin-converting enzyme in spontaneously hypertensive rats. Can J Physiol Pharmacol 88: 168-176.
27. Rademaker MT, Charles CJ, Richards AM (2007) Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol Heart Circ Physiol 293: H1536-H1544.
28. Chen J, Tao J, Zhang R, Xu Y, Soong T et al. (2009) Urocortin inhibits mesenteric arterial remodeling in spontaneously hypertensive rats. Peptides 30: 1117-1123.
29. Torricelli M, Voltolini C, Bloise E, Biliotti G, Giovannelli A et al. (2009) Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-a release from human trophoblast primary cells. Am J Reprod Immunol 62: 224-231.
30. Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M (2007) Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis Rheum 56: 531-543.
31. Kageyama K, Hanada K, Nigawara T, Moriyama T, Terui K et al. (2006) Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 147: 4454-4462.
32. Zhang R, Xu Y, Fu H, Wang J, Jin L et al. (2009) Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells. Br J Pharmacol 158: 819-829.
33. Cureton EL, Ereso AQ, Victorino GP, Curran B, Poole DP et al. (2009) Local secretion of urocortin 1 promotes microvascular permeability during lipopolysaccharide-induced inflammation. Endocrinology 150: 5428-5437.
34. Li W, Challis JR (2005) Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes. J Clin Endocrinol Metab 90: 6569-6574.
35. Xu Y, Zhang R, Chen J, Zhang Q, Wang J et al. (2009) Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. Br J Pharmacol 157: 1368-1379.
36. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N et al. (2000) Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279: H3031-H3039.
37. Ikeda K, Tojo K, Oki Y, Nakano K (2002) Urocortin has cell-proliferative effects on cardiac non-myocytes. Life Sci 71: 1929-1938.
38. Emeto TI, Moxon JV, Biros E, Rush CM, Clancy P et al. (2014) Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2. Clin Sci (Lond) 126: 517-527.
39. Schulman D, Latchman DS, Yellon DM (2002) Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283: H1481-H1488.
40. García-Villalón AL, Amezquita YM, Monge L, Fernández N, Climent B et al. (2005) Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. Br J Pharmacol 145: 490-494.
41. Calderón-Sanchez E, Delgado C, Ruiz-Hurtado G, Domínguez-Rodríguez A, Cachofeiro V et al. (2009) Urocortin induces positive inotropic effect in rat heart. Cardiovasc Res 83: 717-725.
42. Zhu C, Sun Z, Li C, Guo R, Li L et al. (2014) Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal 26: 1125-1134.
43. Lin CS, Lin FY, Ho LJ, Tsai CS, Cheng SM et al. (2012) PKCd signalling regulates SR-A and CD36 expression and foam cell formation. Cardiovasc Res 95: 346-355.
44. Greene EL, Lu G, Zhang D, Egan BM (2001) Signaling events mediating the additive effects of oleic acid and angiotensin II on vascular smooth muscle cell migration. Hypertension 37: 308-312.
45. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R et al. (1997) Compartmentalization of angiotensin II generation in the dog heart. J Clin Invest 100: 253-258.